Mid-Atlantic BioTherapeutics just dropped news that doesn’t just make ripples, it sends a wave across biotech. An investment commitment of up to $50M from Legend Innovation Life Science Fund has the potential to change how we think about aging, neurological decline, and viral diseases. This isn’t about chasing trends. It’s about building the kind of science that survives hype cycles and stands the test of real-world impact.
Founded back in July 2011, Mid-Atlantic BioTherapeutics has never been about small bets. Dr. David Horn, M.D., F.A.C.P., F.I.D.S.A., the company’s CEO and Founder, is a veteran with more than three decades of infectious disease expertise carved out at Bristol-Myers Squibb, Merck, and Thomas Jefferson University. Dr. Dave Jobes, Ph.D., President and Co-Founder, adds over 25 years of research and deal-making muscle, having led more than $500 million in transactions across biotech. Jean-Pierre Gagnon, Ed.D., Senior VP of Operations and Co-Founder, brings serious weight too, formerly President of Merck Mexico, where he oversaw global launches that reshaped entire therapeutic markets. Together, this leadership team looks less like a startup experiment and more like a strike force with receipts.
This funding comes on the back of milestones that are already reshaping their pipeline. Their lead rabies therapy has FDA Orphan Drug Designation, and if successful in the clinic, it could qualify for a Priority Review Voucher, one of the most valuable accelerators in drug development. The company expects to launch a Phase 3 trial for its viral encephalitis program in 2026, pushing further into areas where treatment options remain painfully scarce. Add in a research partnership with Accelero Biostructures targeting USP30 inhibitors for neurodegenerative conditions like Alzheimer’s and Parkinson’s, and you start to see a strategy that’s less shotgun and more sniper rifle.
Technology is the other piece of the story. Their IMT504 platform, a proprietary immunomodulatory oligodeoxynucleotide, has shown survival benefits in preclinical models that rival standard antibiotic therapy. Their AI computational chemistry and structure-based discovery platform sharpen that edge, making it possible to uncover therapeutic opportunities that older models of drug discovery simply miss. When you pair that with Orphan Drug exclusivity on the rabies program, you see a company leveraging science and regulation with equal skill.
The growth play is as ambitious as the science. Funds from Legend will push them toward regulatory milestones, AI-driven programs in oncology and anti-aging, and the setup of a biotech facility in Songdo, Incheon, South Korea. Add the plan for a public listing, IPO or reverse merger, within the next 18 months, and you realize this is not a quiet lab story. It is a company scaling toward a global footprint while staying true to the grind of clinical validation.
Congratulations to Dr. David Horn, Dr. Dave Jobes, Dr. Jean-Pierre Gagnon, and the Mid-Atlantic BioTherapeutics team. And props to Dr. Syngbum (Ben) Kim and Legend Innovation Life Science Fund for backing not just a biotech, but a bet on the future of how we treat aging and disease. This is the kind of deal that reminds us why biotech isn’t for the faint of heart; it’s for the bold who take on problems the rest of us were told were untouchable.
